Effects of cyclooxygenase inhibitors on nitric oxide production and survival in a mice model of sepsis

Pharmacological Research

Volumn 48, Issue 1, 2003, Pages 37-48

  Tunçtan, Bahar ^a,b   Altug, Sedat ^a   Uludag, Orhan ^a   Demirkay, Beray ^a   Abacioglu, Nurettin ^a  

^a GAZI UNIVERSITY   (Turkey)

^b MERSIN UNIVERSITY   (Turkey)

Author keywords

Brain; Endotoxin; Kidney; Lung; Nitric oxide; Serum

Indexed keywords

5,5 DIMETHYL 3 (3 FLOROPHENYL) 4 [4 METHYLSULFONYL 2(5H) FURANONE]; 6 OXOPROSTAGLANDIN F1 ALPHA; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ENDOTOXIN; FURANONE DERIVATIVE; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NITRIC OXIDE; NITRITE; PROQUAZONE; PROSTACYCLIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN; CONTROLLED STUDY; DRUG EFFECT; FEMALE; KIDNEY; LUNG; MALE; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEPSIS; SERUM;

EID: 0037954631     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-6618(03)00064-1     Document Type: Article

References (71)

1. Bone R.C., Balk R.A., Cerra F.B., Dellinger R.P., Fein A.M., Knaus W.A.et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 101:1992;1644-1655.
2. Lehr H.-A., Bittinger F., Kirckpatrick C.J. Microcirculatory dysfunction in sepsis: a pathogenetic basis for therapy. J. Pathol. 190:2000;373-386.
3. Titheradge M.A. Nitric oxide and septic shock. Biochim. Biophys. Acta. 411:1999;437-455.
4. Vincent J.-L. Update on sepsis: pathophysiology and treatment. Acta Clinica Belgica. 55:2000;79-87.
5. Takada H, Kotani S. Structure-function relationships of lipid A. In: Morrison DC, Ryan JL, editors. Bacterial endotoxic lipopolysaccharides: molecular biochemistry and cellular biology, vol. I. USA: CRC Press, Inc.; 1992. p. 107-34.
6. Casey L.C. Immunologic response to infection and its role in septic shock. Crit. Care Clin. 16:2000;193-213.
7. Murray P.T., Wylam M.E., Umans J.G. Nitric oxide and septic vascular dysfunction. Anesth. Analg. 90:2000;89-101.
8. Shah A.M. Inducible nitric oxide synthase and cardiovascular diseases. Cardiovasc. Res. 45:2000;148-155.
9. Strand O.A., Leone A., Giercksky K.E., Kirkeboen K.A. Nitric oxide indices in human septic shock. Crit. Care Med. 28:2000;2779-2785.
10. Vallance P, Rees D, Moncada S. Therapeutic potential of NOS inhibitors in septic shock. In: Born GVR, Cuatrecasas P, Ganten D, Herken H, Starke K, Taylor P, editors. Handbook of experimental pharmacology, vol. 143. Germany: Springer; 2000. p. 385-97.
11. Wray G.M., Foster S.J., Hinds C.J., Thiemermann C. A cell wall component from pathogenic and non-pathogenic Gram-positive bacteria (peptidoglycan) synergises with endotoxin to cause the release of tumour necrosis factor-alpha, nitric oxide production, shock, and multiple organ injury/dysfunction in the rat. Shock. 15:2001;135-142.
12. Bogdan C. The function of nitric oxide in the immune system. In: Born GVR, Cuatrecasas P, Ganten D, Herken H, Starke K, Taylor P, editors. Handbook of experimental pharmacology, vol. 143. Germany: Springer; 2000. p. 443-92.
13. Mcnaughton L, Radomski A, Sawicki G. Regulation of platelet function. In: Born GVR, Cuatrecasas P, Ganten D, Herken H, Starke K, Taylor P, editors. Handbook of experimental pharmacology, vol. 143. Germany: Springer; 2000. p. 235-57.
14. Hon W.M., Khoo H.E., Moochhala S. Nitric oxide in septic shock: directions for future therapy. Ann. Acad. Med. Singapore. 27:1998;414-421.
15. Ketteler M., Cetto C., Kirdorf M., Jeshke G.S., Schäfer J.H., Distler A. Nitric oxide in sepsis-syndrome: potential treatment of septic shock by nitric oxide synthase antagonists. Kidney Int. 53:1998;S27-S30.
16. Kirkebøen K.A., Strand Ø.A. The role of nitric oxide in sepsis - an overview. Acta Anaesthesiol. Scand. 43:1999;275-288.
17. Wolfe T.A., Dasta J.F. Use of nitric oxide synthase inhibitors as a novel treatment for septic shock. Ann. Pharmacother. 29:1995;36-46.
18. Wolkow P.P. Involvement and dual effects of nitric oxide in septic shock. Inflamm. Res. 47:1998;152-166.
19. Dubois R.N., Abramson S.B., Crofford L., Gupta RA L.S., van de Putte L.B.A., Lipsky P.E. Cyclooxygenase in biology and disease. FASEB J. 12:1998;1063-1073.
20. Horn K.D. Evolving strategies in the treatment of sepsis and systemic inflammatory response syndrome (SIRS). Q. J. Med. 91:1998;265-277.
21. Silver R.M., Edwin S.S., Trautman M.S., Simmons D.L., Branch D.W., Dudley D.J.et al. Bacterial lipopolysaccharide-mediated fetal death. Production of a newly recognized form of inducible cyclooxygenase (COX-2) in murine decidua in response to lipopolysaccharide. J. Clin. Invest. 95:1995;725-731.
22. Weikert L.F., Bernard G.R. Pharmacotherapy of sepsis. Clin. Chest Med. 17:1996;289-305.
23. Arons M.M., Wheeler A.P., Bernard G.R., Christman B.W., Russell J.A., Schein R.et al. Effect of ibuprofen on the physiology and survival of hypothermic sepsis. Ibuprofen in Sepsis Study Group. Crit. Care Med. 27:1999;699-707.
24. Ashorobi R.B., Williams P.A. Indomethacin and alpha-tocopherol enhanced survival in endotoxic rats. Cent. Afr. J. Med. 41:1995;216-219.
25. Bernard G.R., Wheeler A.P., Russel J.A., Schein R., Summer W.R., Steinberg K.P.et al. The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. N. Engl. J. Med. 336:1997;912-918.
26. Mansilla-Rosello A., Ferron-Orihuela J.A., Ruiz-Cabello F., Garrote-Lara D., Fernandez-Mondejar E., Delgado-Carrasco M.L. Differential effects of IL-1 beta and ibuprofen after endotoxic challenge in mice. Surg. Res. 67:1997;199-204.
27. Noble S.L., King D.S., Olutade J.I. Cyclooxygenase-2 enzyme inhibitors: place in therapy. Am. Fam. Physician. 61:2000;3669-3676.
28. Pepper G.A. Nonsteroidal anti-inflammatory drugs: new perspectives on a familiar drug class. Nurs. Clin. North Am. 35:2000;223-244.
29. Tseng C.C., Wolfe M.M. Nonsteroidal anti-inflammatory drugs. Med. Clin. North Am. 84:2000;1329-1344.
30. Di Rosa M., Ialenti A., Ianaro A., Sautebin L. Interaction between nitric oxide and cyclooxygenase pathways. Prostaglandins Leukot. Essent. Fatty Acids. 54:1996;229-238.
31. Goodwin D.C., Landino L.M., Marnett L.J. Effects of nitric oxide and nitric oxide-derived species on prostaglandin endoperoxide synthase and prostaglandin biosynthesis. FASEB J. 13:1999;1121-1136.
32. 2 levels induced by lipopolysaccharide in mice. Biol. Rhythm. Res. 31:2000;499-514.
33. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:1951;265-271.
34. Cantoni L., Di Nicolantonio F., Barelli D., Rizzardini M., De Matteis F. Modulation of cerebellar and hepatic nitric oxide synthase by exogenous arginine and endotoxin. Nitric Oxide. 5:2001;198-207.
35. Tunçtan B., Altug S., Uludag O., Abacioglu N. Effects of nitric oxide synthase inhibition in lipopolysaccharide-induced sepsis in mice. Pharmacol. Res. 38:1998;405-411.
36. Vodovotz Y., Kopp J.B., Takeguchi H., Shrivastav S., Coffin D., Lucia M.S.et al. Increased mortality, blunted production of nitric oxide, and increased production of TNF-α in endotoxemic TGF-β1 transgenic mice. J. Leukoc. Biol. 63:1998;31-39.
37. Cunha F.Q., Assreuy J., Moss D.W. Differential induction of nitric oxide synthase in various organs of the mouse during endotoxaemia: role of TNF-alpha and IL-1-beta. Immunology. 81:1994;211-215.
38. 2+-independent nitric oxide synthases. FEBS. 291:1991;145-149.
39. Ter Steege J.C., Van De Ven W.C., Forget P.P., Buurman W.A. Regulation of lipopolysaccharide-induced NO synthase expression in the major organs in a mouse model. The roles of endogenous interferon-gamma, tumor necrosis factor-alpha and interleukin-10. Eur. Cytokine Netw. 11:2000;39-46.
40. Salter M., Duffy C., Garthwaite J., Strijbos P.J. Ex vivo measurement of brain tissue nitrite and nitrate accurately reflects nitric oxide synthase activity in vivo. J. Neurochem. 66:1996;1683-1690.
41. Boje K.M. Inhibition of nitric oxide synthase attenuates blood-brain barrier disruption during experimental meningitis. Brain Res. 720:1996;75-83.
42. Okamoto H., Ito O., Roman R.J., Hudetz A.G. Role of inducible nitric oxide synthase and cyclooxygenase-2 in endotoxin-induced cerebral hyperemia. Stroke. 29:1998;1209-1218.
43. Thiel V.E., Audus K.L. Nitric oxide and blood-brain integrity. Antioxid. Redox Signal. 3:2001;273-278.
44. Tunçtan B., Weigl Y., Dotan A., Peleg L., Zengil H., Ashkenazi I.et al. Circadian variation of nitric oxide synthase activity in mouse tissue. Chronobiol. Int. 19:2002;1-12.
45. Pairet M, Van Ryn J, Mauz A, Schierok H, Diederen W, Türck D, et al. Differential inhibition of COX-1 and COX-2 by NSAIDs: a summary of results obtained using various test systems. In: Vane SR, Botting JH, editors. Selective COX-2 inhibitors. Pharmacology, clinical effects and therapeutic potential. England: Kluwer Academic Publishers; 1998. p. 27-46.
46. 2 formation is increased in human sepsis syndrome. Effects of cyclooxygenase inhibition. Am. Rev. Respir. Dis. 144:1991;1095-1101.
47. Menges T., Engel J., Welters I., Wagner R.M., Little S., Ruwoldt R.et al. Changes in blood lymphocyte populations after multiple trauma: association with posttraumatic complications. Crit. Care Med. 27:1999;733-740.
48. Mozes T., Heiligers J.P., Tak C.J., Zijlstra F.J., Ben-Efraim S., Saxena P.R.et al. Protective effect of diclophenac sodium against endotoxic shock in anaesthetized pigs. Prostaglandins Leukot. Essent. Fatty Acids. 48:1993;193-200.
49. Pettipher E.R., Wimberley D.J. Cyclooxygenase inhibitors enhance tumour necrosis factor production and mortality in murine endotoxic shock. Cytokine. 6:1994;500-503.
50. Riendeau D., Percival M.D., Boyce S., Brideau C., Charleson S., Cromlish W.et al. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor. Br. J. Pharmacol. 121:1997;105-117.
51. Chan C.C., Panneton M., Taylor A.M., Therien M., Rodger I.W. A selective inhibitor of cyclooxygenase-2 reverses endotoxin-induced pyretic responses in non-human primates. Eur. J. Pharmacol. 327:1997;221-225.
52. Salvemini D., Misko T.P., Masferrer J.L., Seibert K., Currie M.G., Needleman P. Nitric oxide activates cyclooxygenase enzymes. Proc. Natl. Acad Sci. U.S.A. 90:1993;7240-7244.
53. Watkins D.N., Garlepp M.J., Thompson P.J. Regulation of the inducible cyclo-oxygenase pathway in human cultured airway epithelial (A549) cells by nitric oxide. Br. J. Pharmacol. 121:1997;1482-1488.
54. Salvemini D., Settle S.L., Masferrer J.L., Seibert K., Currie M.G. Regulation of prostaglandin production by nitric oxide; an in vivo analysis. Br. J. Pharmacol. 114:1995;1171-1178.
55. Sautebin L., Di Rosa M. Nitric oxide modulates prostacyclin biosynthesis in the lung of endotoxin-treated rats. Eur. J. Pharmacol. 262:1994;193-196.
56. Soler M., Camacho M., Molins-Pujol A.M., Vila L. Effect of an imidazolineoxyl nitric oxide on prostaglandin synthesis in experimental shock: possible role of nitrogen dioxide in prostacyclin synthase inactivation. J. Infect. Dis. 183:2001;105-112.
57. Amin A.R., Vyas P., Aattur M., Leszczynska-Piziak J., Patel I., Weissmann G.et al. The mode of action of aspirin-like drugs: effect on inducible nitric oxide synthase. Proc. Natl. Acad Sci. U.S.A. 92:1997;7926-7930.
58. Habib A., Bernard C., Lebret M., Créminon C., Esposito B., Tedgui A.et al. Regulation of the expression of cyclooxygenase-2 by nitric oxide in rat peritoneal macrophages. J. Immunol. 158:1997;3845-3851.
59. Swierkosz T.A., Mitchell J.A., Warner T.D., Botting R.M., Vane J.R. Co-induction of nitric oxide synthase and cyclo-oxygenase: interactions between nitric oxide and prostanoids. Br. J. Pharmacol. 114:1995;1335-1342.
60. Boquet M., Cebral E., Motta A., Beron de Astrada M., Gimeno M.A. Relationship between mouse uterine contractility, nitric oxide and prostaglandin production in early pregnancy. Prostaglandins Leukot. Essent. Fatty Acids. 59:1998;163-167.
61. Curtis J.F., Reddy N.G., Mason R.P. Nitric oxide: a prostaglandin H synthase 1 and 2 reducing cosubstrate that does not stimulate cyclooxygenase activity or prostaglandin H synthase expression in murine macrophages. Arch. Biochem. Biophys. 335:1996;369-376.
62. Hamilton L.C., Warner T.D. Interactions between inducible isoforms of nitric oxide synthase and cyclo-oxygenase in vivo: investigations using the selective inhibitors. Br. J. Pharmacol. 125:1998;335-340.
63. Marotta P., Sautebin L., Di Rosa M. Modulation of the induction of nitric oxide synthase by eicosanoids in the murine macrophage cell line J774.2 cells. Br. J. Pharmacol. 107:1992;640-641.
64. Raddasi K., Petit J.F., Lemaire G. LPS-induced activation of primed murine peritoneal macrophages is modulated by prostaglandins and cyclic nucleotides. Cell Immunol. 149:1993;50-64.
65. 2 of cytokine-elicited nitric oxide synthesis in rat liver macrophages. Biol. Chem. 373:1992;897-902.
66. 2 regulates inducible nitric oxide synthase in the murine macrophage cell line J774. Prostaglandins. 49:1995;105-115.
67. Liang J.F., Akaike T. Inhibition of lipopolysaccharide and cytokine mixture-mediated hepatocyte nitric oxide synthesis by dimethyl sulfoxide. Biochem. Biophys. Res. Commun. 239:1997;517-521.
68. Greenberg S.S., Xie J., Wang Y., Kolls J., Malinski T., Summer W.R.et al. Ethanol suppresses LPS-induced mRNA for nitric oxide synthase II in alveolar macrophages in vivo and in vitro. Alcohol. 11:1994;539-547.
69. Greenberg S.S., Ouyang J., Zhao X. Interaction of ethanol with inducible nitric oxide synthase messenger RNA and protein: direct effects on autocoids and endotoxin in vivo. J. Pharmacol. Exp. Ther. 282:1997;1044-1054.
70. Naassila M., Roux F., Beauge F., Daoust M. Ethanol potentiates lipopolysaccharide- or interleukin-1 beta-induced nitric oxide generation in RBE4 cells. Eur. J. Pharmacol. 313:1996;273-277.
71. Zhao X., Jie O., Li H., Xie J., Giles T.D., Greenberg S.S. Ethanol inhibits inducible nitric oxide synthase transcription and post-transcriptional processes in vivo. Alcohol Clin. Exp. Res. 21:1997;1246-1256.